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Satish Kenchaiah, MD, MPH; Connie W. Tsao, MD; Susan B. Yeon, MD, JD; Renate B. Schnabel, MD, MSc; John F. Keaney, MD;
Christopher J. O’Donnell, MD, MPH; Emelia J. Benjamin, MD, ScM; Warren J. Manning, MD
Background-—The relations between subclinical atherosclerosis and inﬂammatory biomarkers have generated intense interest but
their signiﬁcance remains unclear. We sought to determine the association between a panel of biomarkers and subclinical aortic
atherosclerosis in a community-based cohort.
Methods and Results-—We evaluated 1547 participants of the Framingham Heart Study Offspring cohort who attended the 7th
examination cycle and underwent both cardiovascular magnetic resonance imaging (CMR) and assays for 10 biomarkers
associated with atherosclerosis: high-sensitivity C-reactive protein, ﬁbrinogen, intercellular adhesion molecule-1, interleukin-6,
interleukin-18, lipoprotein-associated phospholipase-A2 activity and mass, monocyte chemoattractant protein-1, P-selectin, and
tumor necrosis factor receptor-2. In logistic regression analysis, we found no signiﬁcant association between the biomarker panel
and the presence of aortic plaque (global P=0.53). Using Tobit regression with aortic plaque as a continuous variable, we noted a
modest association between biomarker panel and aortic plaque volume in age- and sex-adjusted analyses (P=0.003). However, this
association was attenuated after further adjustment for clinical covariates (P=0.09).
Conclusions-—In our community-based cohort, we found no signiﬁcant association between our multibiomarker panel and aortic
plaque. Our results underscore the strengths and limitations of the use of biomarkers for the identiﬁcation of subclinical athero-
sclerosis and the importance of traditional risk factors. (J Am Heart Assoc. 2013;2:e000307 doi: 10.1161/JAHA.113.000307)
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C
ardiovascular disease (CVD) due to atherosclerosis is the
leading cause of morbidity and mortality in the indus-
trialized world.
1,2 As a result, there is signiﬁcant interest in
early identiﬁcation of individuals at risk for atherosclerosis in
order to optimally target primary prevention.
3 Aortic atheroma
is a manifestation of systemic atherosclerosis
4–7 and calciﬁed
atheroma in the abdominal and thoracic aorta strongly predict
increased risk for CVD outcomes adjusting for traditional risk
factors.
8–12 Inﬂammation plays a central role in atheroscle-
rosis and several individual inﬂammatory biomarkers have
been associated with atherosclerosis, including high-sensitiv-
ity C-reactive protein, ﬁbrinogen, and tumor necrosis factor
receptor-2.
3,13–16
Inﬂammatory biomarkers have been correlated with sub-
clinical atherosclerosis by 2-dimensional noninvasive imaging
techniques including high-resolution B-mode carotid ultra-
sound
13,17 and epicardial coronary calciﬁcation by electron
beam computed tomography.
18–20 However, there are limited
data regarding associations between these biomarkers and
aortic plaque, as deﬁned by a contemporary, advanced non-
invasive imaging modality such as cardiovascular magnetic
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ORIGINAL RESEARCHresonance imaging (CMR). CMR has the ability to measure the
entire aorta (ascending and descending) in 3 dimensions,
thereby increasing the detection of subclinical aortic ather-
oma. CMR offers unique advantages as a noninvasive
technique for the identiﬁcation of aortic atheroma, including
highly reproducible measurements of aortic anatomy, quan-
tiﬁcation of atherosclerosis, and lack of ionizing radiation.
21
We sought to determine the association between a panel of
10 biomarkers associated with atherosclerosis and aortic
plaque, as determined by CMR, and performed an exploratory
analysis to assess for effect modiﬁcation of the associations
between inﬂammatory biomarkers and aortic plaque by sex,
in a longitudinally followed community-based cohort.
Methods
Study Population and Sample Selection
The Framingham Offspring Study was initiated in 1971 when
5124 adult children (and offspring spouses) of the Original
Framingham Heart Study (FHS) Cohort were enrolled.
Offspring participants have been examined approximately
every 4 to 7 years since the study’s inception. Offspring
participants who attended the 7th examination cycle (1998-
2001) were eligible for the present study (n=3799), of whom
1794 were in sinus rhythm, lived in Massachusetts or a
contiguous state, and had no contraindications to CMR.
Assays for several biomarkers were also measured during
this cycle visit, as previously described.
22 Only participants
who had both a CMR and the panel of biomarkers were
included in this study. The study was approved by the
Institutional Review Boards of the Boston University Medical
Center and the Beth Israel Deaconess Medical Center.
Written informed consent was obtained from all participants.
Cardiovascular Magnetic Resonance (CMR)
Participants underwent thoracoabdominal aortic CMR using a
1.5-T whole-body CMR system (Gyroscan ACS-NT; Philips
Medical Systems) as previously reported.
23 Thirty-six transverse
slices encompassing the aorta from the arch to the aortoiliac
bifurcationwereobtainedusingafree-breathing,ECG-gated,fat-
suppressed, black blood 2D T2-weighted turbo spin-echo
sequence with in-plane spatial resolution of 1.0390.64 mm
2
and 5 mm slice thickness. Twelve slices with a 10 mm slice gap
was used for the thoracic aorta and a denser sampling of 24
slices with a 5 mm gap was used for the abdominal aorta.
Aortic and Atherosclerotic Plaque Analysis
A single expert reviewer (N.O.) blinded to all clinical data
analyzed CMR images using commercial software (QMASS
v 6.1; QT-MEDIS).
23 Atherosclerotic plaque was deﬁned as
characteristic luminal protrusions of ≥1 mm in radial thick-
ness that could be visually distinguished from the minimal
residual blood signal of each plaque. For each participant,
plaque cross-sectional areas were measured at each slice
(descending thoracic and abdominal) and total plaque volume
was calculated. Individual plaque volume was also normalized
for calculated body surface area (BSA) based on 7th
examination cycle. Intra- and inter-reader reproducibility or
aortic plaque volume was good with intraclass correlation
coefﬁcients of 0.99 and 0.94, respectively.
23
Biomarker Selection and Measurement
We selected a panel of 10 biomarkers available at
Cycle 7 that were associated with vascular inﬂammation
and atherosclerosis; criteria for selection were previously
described.
22,24,25 These included high-sensitivity C-reactive
protein (hs-CRP, a marker of inﬂammation); ﬁbrinogen (a
marker of thrombosis and inﬂammation); intercellular adhe-
sion molecule-1 (a marker associated with progressive
atherosclerotic plaque); interleukin-6 (a pro-inﬂammatory
marker); interleukin-18 (a pro-inﬂammatory marker); lipopro-
tein-associated phospholipase A2 activity and mass (a low-
density lipoprotein particle thought to promote atherosclero-
sis); monocyte chemoattractant protein-1, (a chemokine
associated with damaged endothelium and atherosclerotic
plaque); P-selectin (a marker associated with inﬂammatory
cell adhesion and atherosclerosis); and tumor necrosis factor
receptor-2 (a marker of inﬂammation associated with athero-
sclerotic plaque).
Blood samples were collected from fasting participants and
stored at 80°C until analysis. Details for biomarker
measurements have been described elsewhere.
22 The intra-
assay coefﬁcients of variation for the biomarkers were <8%.
Clinical Covariate Assessment
We obtained clinical covariates at the time of the Cycle 7
examination. Medication use (including lipid-lowering treat-
ment and aspirin) and current smoking within the year
preceding the exam were self reported. Hypertension was
deﬁned as systolic blood pressure of ≥140 mm Hg, diastolic
≥90 mm Hg, or use of any antihypertensive medication. Body
mass index was calculated as weight in kilograms divided by
the height in meters squared. Diabetes was deﬁned as fasting
blood glucose of ≥126 mg/dL or use of insulin or oral
hypoglycemic agents. An endpoint adjudication panel con-
sisting of 3 investigators determined prevalent CVD (angina
pectoris, coronary insufﬁciency, myocardial infarction, stroke,
transient ischemic attack, or heart failure), using standardized
criteria.
26
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We summarized data on demographics and clinical covariates
using mean1 standard deviation (SD) or median (25th, 75th
percentile) for continuous variables and percentages for
categorical variables. We natural log-transformed biomarkers
and plaque volumes (cm
3) and standardized them to mean=0
and SD=1 to normalize the skewed distribution. Linear
correlations between pairs of biomarkers have been previously
described and are described in Table 1.
27 We used logistic
regression models to examine the association between inﬂam-
matory biomarkers and presence/absence of aortic plaque.
Further, because approximately half the participants did not
have evidence of aortic plaque on CMR, we used Tobit
regression to evaluate the association between inﬂammatory
biomarkers and aortic plaque volume as a continuous variable.
Tobit models are censored regression models that are applica-
ble when a seemingly normally distributed dependent variable
has ﬂoor or ceiling effects.
28 In multivariable models, we
adjusted for age at CMR scan and the following covariates
collected at Cycle 7 examination: sex, body mass index,
cigarette smoking, hypertension, diabetes mellitus, total/HDL
cholesterol, lipid-lowering treatment, and prevalent CVD.
To reduce inﬂation of Type I error due to multiple testing,
we determined a “global” P value for the biomarker panel as a
whole using a likelihood ratio test, which, in our case, was a v²
test with 10 degrees of freedom calculated as—2 log-
likelihood for the model with clinical covariates and 10
biomarkers minus 2 log-likelihood for the model with clinical
covariates only. If the global P-value reached statistical
signiﬁcance (2-sided P<0.05), we planned to use backward
elimination to select a parsimonious set of informative
biomarkers with P<0.05 for retention in the ﬁnal model.
Lastly, to assess for effect modiﬁcation of the associations
betweeninﬂammatorybiomarkers andaorticplaquebysex,we
included interaction terms in age-adjusted regression models
foreachbiomarker.Intheseanalyses,weaccountedformultiple
testingbyapplyingBonferroniadjustment;aP≤0.005wasused
to indicate statistical signiﬁcance for each interaction term.
We used the SAS procedures PROC LOGISTIC, PROC REG,
and PROC LIFEREG with normal distribution option to ﬁt
logistic, linear, and Tobit regression models, respectively. We
conducted all analyses using SAS Version 9.3 (SAS Institute).
Results
Participant Characteristics
Of the 1794 Offspring participants who underwent aortic CMR
imaging, 31 (1.7%) were incomplete, 28 (1.6%) did not have
plaque data, 37 (2.1%) had poor image quality precluding
measurement of aortic plaques, 34 (1.8%) did not have
biomarker data, and 148 (8.2%) had at least 1 missing
covariate, leaving 1547 participants (86%) eligible for analysis.
Table 1. Age- and Sex-adjusted Correlations Among Biomarkers*
Other Biomarker CRP Fibrinogen ICAM-1 IL-6 IL-18 LpPLA2a LpPLA2m MCP-1 P-selectin TNFR-2
CRP 1.000
Fibrinogen 0.45442
<0.0001
1.000
ICAM-1 0.19187
<0.0001
0.17618
<0.0001
1.000
IL-6 0.45274
<0.0001
0.35347
<0.0001
0.23445
<0.0001
1.000
IL-18 0.16938
<0.0001
0.10856
<0.0001
0.30983
<0.0001
0.20336
<0.0001
1.000
LpPLA2a 0.02645
0.2985
0.03074
0.2268
0.19527
<0.0001
0.06418
0.0116
0.20820
<0.0001
1.000
LpPLA2m 0.00340
0.8938
0.02667
0.2946
0.10704
<0.0001
0.06697
0.0084
0.11828
<0.0001
0.49874
<0.0001
1.000
MCP-1 0.09032
0.0004
0.04237
0.0958
0.07876
0.0019
0.15891
<0.0001
0.05286
0.0376
0.01397
0.5830
0.03045
0.2313
1.000
P-selectin 0.14125
<0.0001
0.12454
<0.0001
0.17588
<0.0001
0.15488
<0.0001
0.10669
<0.0001
0.07319
0.0040
0.06826
0.0072
0.09192
0.0003
1.000
TNFR-2 0.21070
<0.0001
0.18052
<0.0001
0.35456
<0.0001
0.29168
<0.0001
0.32732
<0.0001
0.18794
<0.0001
0.16364
<0.0001
0.10588
<0.0001
0.14134
<0.0001
1.000
CRP indicates C-reactive protein; ICAM-1, intracellular adhesion molecule-1; IL-6, interleukin-6; IL-18, interleukin-18; LpPLA2a, lipoprotein-associated phospholipase A2 activity; LpPLA2m,
lipoprotein-associated phospholipase A2 mass; MCP-1, monocyte chemoattractant protein-1; TNFR-2, tumor necrosis factor receptor 2.
*Values are age- and sex-adjusted Spearman’s rank correlation coefﬁcients (n=1547).
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healthier cohort (3 years younger, less obese, lower systolic
blood pressure, smoked less, less hypertensive, less likely to
be diabetic, less likely to be on lipid lowering medication or
antihypertensive medications, and less likely to have
prevalent CVD) (Table 2). These differences are likely due to
the fact that the population who underwent CMR had to be
free of prevalent CVD, not be claustrophobic, and not be
above a certain weight in order to ﬁt in the CMR scanner.
Median time between Cycle 7 examination and acquisition
of CMR scans was 4.4 years (1.8, 6.8 years). Our cohort
comprised of middle-aged to older adults, slightly more than
half were women, and 428 (28%) were obese. More detailed
clinical characteristics are listed in Table 3. As previously
reported, 738 of 1547 participants (48%) had evidence of
aortic plaque, predominantly located in the abdomen (plaque
prevalence ratio of abdomen to thorax, 7:1).
23 All those with
thoracic plaque also had abdominal plaque. Among those with
aortic plaque, the median (25th and 75th percentile) plaque
volumes were the following: total plaque burden was 0.4 cm
3
(0.2, 5.5) in men and 0.5 cm
3 (0.2, 3.8) in women; abdominal
plaque burden was 0.5 cm
3 (0.29, 3.8) in men and 0.4 cm
3
(0.26, 3.8) in women; thoracic plaque burden was 0.4 cm
3
(0.2, 4.3) in men and 0.4 cm
3 (0.2, 3.4) in women.
Aortic Atherosclerosis and Biomarkers
Median (25th to 75th percentile) levels of biomarkers by aortic
plaquestatusareshowninTable 4.Afteradjustingforage,sex,
and clinical covariates, the presence of aortic plaque was not
associated with the multibiomarker panel (Global P=0.53)
(Table 5). In age- and sex-adjusted analyses, a modest statis-
tically signiﬁcant association was noted between continuous
aortic plaque volume and multibiomarker panel (Global
P=0.03).However,thisassociationwasattenuatedafterfurther
adjustment for clinical covariates (Global P=0.09). Backward
elimination was not performed because the global P values for
both logistic regression and Tobit regression models after
adjustment for all covariates were greater than 0.05.
Aortic Atherosclerosis, Biomarkers, and Sex
In logistic regression models evaluating aortic plaque as a
dichotomous variable (present/absent), we did not observe
Table 2. Clinical Characteristics at Examination Cycle 7 Among Participants With and Without CMR
Characteristics CMR (n=1547) No CMR (n=2137) P Value
Age, y 6096 3 10 <0.0001
Sex, n (%)
Men 725 (47) 901 (45)
Women 822 (53) 1092 (55) 0.3266
Body mass index, kg/m
2 2852 8 6 0.0009
Obesity, n (%) 42027 56932 0.0030
Total cholesterol, mg/dL 20136 20038 0.3410
Total HDL:total cholesterol 0.270.1 0.270.1 0.5625
Systolic blood pressure, mm Hg 12518 12920 <0.0001
Diastolic blood pressure, mm Hg 7410 7410 0.2605
HDL cholesterol, mg/dL 5417 5417 0.9674
Alcohol (number of drinks per week) 333 4 0.1121
Triglycerides, mg/dL 13495 14083 0.1121
Current smoker, n (%) 328 (10) 155 (17) <0.0001
Hypertension, n (%) 629 (41) 1006 (51) <0.0001
Diabetes mellitus, n (%) 262 (9) 133 (15) <0.0001
Use of statin medications, n (%) 281 (18) 461 (23) 0.0003
Use of antihypertensive therapy, n (%) 451 (29) 768 (39) <0.0001
Use of hormone replacement therapy, n (%) 276 (18) 276 (16) 0.0717
Daily use of aspirin, n (%) 467 (30) 588 (33) 0.0741
Prevalent cardiovascular disease, n (%) 136 (9) 344 (17) <0.0001
Values are meanstandard deviation or percentages as appropriate. Obesity deﬁned as a body mass index of greater than 30 kg/m
2. CMR indicates cardiovascular magnetic resonance
imaging; HDL, high-density lipoprotein.
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biomarker and presence/absence of aortic atherosclerosis
(Table 6, all P-values >0.09). Similarly, in Tobit regression
analyses restricted to participants with quantiﬁed aortic
plaque volume, we did not note signiﬁcant sex interactions
with any individual biomarker after adjusting for age and
Table 3. Clinical Characteristics at Examination Cycle 7
Characteristics All (n=1547) No Plaque (n=810) Plaque (n=737)
Age, y 6095 8 96 2 9
Sex, n (%)
Men 726 (47) 386 (48) 340 (46)
Women 821 (53) 424 (52) 397 (54)
Body mass index, kg/m
2 2852 8 55 285
Obesity, n (%) 428 (28) 234 (55) 194 (45)
Total cholesterol, mg/dL 20136 20036 20236
LDL-c 12132 12032 12232
Total HDL:total cholesterol 414 14 1
Systolic blood pressure, mm Hg 12518 12417 12718
Diastolic blood pressure, mm Hg 7410 7597 3 10
HDL cholesterol, mg/dL 5417 5417 5317
Alcohol (number of drinks per week) 332 33 4
Triglycerides, mg/dL 13495 13091 13999
Current smoker, n (%) 155 (10) 66 (8) 89 (12)
Hypertension, n (%) 634 (41) 295 (36) 339 (46)
Diabetes mellitus, n (%) 158 (10) 66 (8) 92 (12)
Use of statin medications, n (%) 281 (18) 116 (14) 165 (22)
Use of antihypertensive therapy, n (%) 451 (29) 210 (26) 241 (33)
Use of hormone replacement therapy, n (%) 276 (18) 145 (18) 131 (18)
Daily use of aspirin, n (%) 467 (30) 220 (27) 247 (34)
Prevalent cardiovascular disease, n (%) 52 (3) 13 (2) 39 (5)
Values are meanstandard deviation or percentages as appropriate. Obesity deﬁned as a body mass index >30 kg/m
2. HDL indicates high-density lipoprotein; LDL-c, calculated
low-density lipoprotein.
Table 4. Biomarkers According to Aortic Plaque Status Determined by Cardiovascular Magnetic Resonance Imaging
Biomarker Panel
No Plaque (n=810) Plaque (n=737)
Median 25th, 75th Percentile Median 25th, 75th Percentile
High-sensitivity C-reactive protein, mg/L 1.8 0.9, 4.1 2.0 0.9, 4.9
Fibrinogen, mg/dL 365 323, 405 369 330, 415
Intracellular adhesion molecule-1, ng/mL 234 205, 265 241 209, 280
Interleukin-6, pg/mL 2.3 1.6, 3.7 2.7 1.8, 4.2
Interleukin-18, pg/mL 225 163, 300 238 178, 307
LpPLA2 activity, ng/mL 139 118, 165 140 119, 166
LpPLA2 mass, nmol/(mL min) 285 228, 358 283 228, 353
Monocyte chemoattractant protein-1, pg/mL 300 242, 370 310 251, 387
P-selectin, pg/mL 35 28, 43 36 28, 45
Tumor necrosis factor receptor-2, pg/mL 1896 1606, 2292 1971 1677, 2367
LpPLA2 indicates lipoprotein-associated phospholipase A2.
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in the panel of 10, we conducted post-hoc statistical power
calculations and determined that at most we had 52%
statistical power to detect the odds ratio associated with a
1 standard deviation unit of the logarithm of the biomarker
value. Therefore, we did not have sufﬁcient power to
detect a clinically signiﬁcant effect of the biomarkers
studied.
Discussion
In our community-based study, we found no statistically
signiﬁcant associations between a panel of inﬂammatory and
atherosclerotic biomarkers and aortic plaque (presence or
volume) after adjustment for age, sex, and clinical covariates.
While our secondary analyses also found no interaction
between any biomarker and sex among participants with
aortic plaque after multivariable adjustment, we did not have
sufﬁcient power to detect a clinically signiﬁcant effect of the
biomarkers studied.
Our results differ from that of prior studies, which found
associations between similar biomarkers and other noninva-
sive measures of atherosclerosis among a comparable
cohort.
13,17,20 This disparity may be due to several factors.
First, previous studies predominantly used carotid ultrasound
and x-ray techniques (coronary calcium) for noninvasive
measures of atherosclerosis. CMR is a specialized, advanced
imaging modality and its ability to detect and measure aortic
plaque among asymptomatic individuals may be more sensi-
tive due to its greater anatomical coverage (abdominal and
thoracic aorta versus carotid/coronary arteries). As men-
tioned earlier, nearly half of our cohort (48%, n=738) had
evidence of subclinical atheroma by CMR. Consequently, CMR
may identify subclinical atherosclerosis in participants with
normal or marginally elevated biomarkers, thus attenuating
any signiﬁcant associations and biasing our results toward the
null. Also, whereas our biomarker panel and CMR scans were
conducted within the same examination cycle (Cycle 7), they
Table 5. Results of Regression Models Examining the
Association Between Circulating Biomarker Levels
and Aortic Plaque
Description of Model
v
2 Statistic
(10 degrees of freedom)
Global
P Value
Logistic Regression Models
(Aortic plaque as a dichotomous variable, yes/no)
Adjusted for age and sex 15.9 0.10
Adjusted for age, sex,
and other covariates*
9.0 0.53
Tobit Regression Models
(Aortic plaque as a continuous variable, per cm
3 increase)
Adjusted for age and sex 26.4 0.003
Adjusted for age, sex,
and other covariates*
16.5 0.09
*Adjusted for the following covariates at exam cycle 7: age at CMR scan, body mass
index, hypertension, total cholesterol/high density lipoprotein, sex, lipid lower treatment,
smoking, diabetes, and prevalent cardiovascular disease.
Table 6. P Values for Effect Modiﬁcation Between Sex and Individual Biomarkers in Logistic and Tobit Regression Models
Predicting Aortic Plaque (Binary and Continuous Aortic Plaque)
Biomarker
P Values*
Logistic Regression Models
† Tobit Regression Models
‡
Age-Adjusted Multivariable-Adjusted
§ Age-Adjusted Multivariable-Adjusted
§
High-sensitivity C-reactive protein, mg/L 0.86 0.64 0.01 0.04
Fibrinogen, mg/dL 0.83 0.99 0.15 0.17
Intracellular adhesion molecule-1, ng/mL 0.16 0.09 0.02 0.03
Interleukin-6, pg/mL 0.29 0.24 0.09 0.06
Interleukin-18, pg/mL 0.87 0.99 0.42 0.43
LpPLA2 activity, ng/mL 0.53 0.99 0.82 0.47
LpPLA2 mass, nmol/(mL min) 0.61 0.90 0.31 0.17
Monocyte chemoattractant protein-1, pg/mL 0.28 0.29 0.35 0.38
P-selectin, pg/mL 0.20 0.32 0.04 0.06
Tumor necrosis factor receptor-2, pg/mL 0.10 0.13 0.04 0.05
LpPLA2 indicates lipoprotein-associated phospholipase A2.
*Bonferroni adjusted P<0.005 was used to indicate statistical signiﬁcance.
†Aortic plaque was modeled as a dichotomous variable, yes/no.
‡Aortic plaque was modeled as a continuous variable, per cm
3 increase.
§Adjusted for age, body mass index, cigarette smoking, hypertension, diabetes mellitus, total/HDL cholesterol ratio, lipid lower treatment, and prevalent cardiovascular disease.
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Heart Study investigations with even greater time delays (eg,
Cycle 5 biomarkers, Cycle 6 imaging, median time between
biomarker acquisition and imaging >6 years) were still able to
ﬁnd relationships between a similar panel of biomarkers and
noninvasive imaging.
17,20 Additionally, aortic atherosclerosis
measured by CMR may represent a very early form of plaque
burden, which initiates in the abdomen and is only seen in the
thorax, coronaries, and carotid arteries much later in its
progression. It may be that this early form of atherosclerosis
may not be strongly associated with our biomarker panel,
which has been associated with atheroma in the coronaries
and carotid arteries. Furthermore, these biomarkers also may
be closely associated with clinical states leading to the
development of atherosclerosis (eg, obesity, elevated choles-
terol, diabetes), which may explain the attenuation of
statistical signiﬁcance after further adjustment for clinical
covariates. Our ﬁndings are consistent with a systematic
review of 12 studies assessing the relationship of similar
biomarkers (hs-CRP, MCP-1, LpPLA2, IL-6) with coronary
calcium that found weak relationships that were no longer
signiﬁcant when corrected for traditional risk factors.
19
Our results underscore the strengths and limitations of the
use of biomarkers for the identiﬁcation of subclinical
atherosclerosis and the importance of traditional risk factors.
Whereas multiple biomarkers have been associated with
subclinical CVD, by themselves, they each provide minimal
incremental value to predict subclinical atherosclerosis for an
individual person after a noninvasive assessment. Moreover,
despite the considerable interest in identifying participants
with subclinical atherosclerosis and CVD risk through
biomarkers, studies using speciﬁc biomarkers have generally
shown only modest effects over and above traditional risk
factors.
29–31
Strengths and Limitations
The strengths of this study include the community-based
cohort design, the rigorous biomarker quality control, a single-
expert CMR reader for aortic plaque measurements blinded to
clinical data, and standardized measures of clinical variables.
However, there were several limitations to our analysis that
merit comment. Our study is observational and not designed
to characterize atherosclerotic plaque components or address
clinical outcomes outside of noninvasive imaging. Addition-
ally, our CMR scanning was performed during the 7th
examination cycle (1998-2001) using a 1.5 MRI system,
which was current and up to date for its time. Signiﬁcant
advancements in MRI have occurred since then, including 3T
MRI scanners (approved by the FDA in 2002), which may have
increased the sensitivity of detecting smaller aortic plaques.
We selected inﬂammatory and atherosclerotic biomarkers
based on biological plausibility, prior data, and availability in
our cohort at exam Cycle 7. Although our biomarker panel and
CMR scans were conducted within the same exam cycle, they
were not obtained concomitantly. Medication usage (aspirin,
antihypertensives, and statins) may have affected biomarker
concentrations, particularly among those with evidence of
aortic atheroma. Given the observational study design and
nonrandomized medication usage, our investigation was not
well suited to inform the relations between medications and
subclinical or clinical CVD. Finally the FHS Offspring cohort is
predominantly of European ancestry, which may limit gener-
alizability to individuals to other races/ethnicities.
Conclusion
In our community-based CMR cohort, we found no signiﬁcant
associations between the multibiomarker panel with the
presence or volume of aortic plaque as measured by CMR.
Our ﬁndings highlight the strengths and limitations of
biomarkers for the identiﬁcation of subclinical atherosclerosis
and the importance of traditional risk factors.
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